Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Baseline characteristics in Moderna cancer vaccine 'misleading': Leerink's Dr. Mani Foroohar
05:22pm, Thursday, 22'nd Jan 2026
Dr. Mani Foroohar, Leerink Partners, joins 'Closing Bell Overtime' to talk Moderna prices climbing on positive drug trial.
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
12:40pm, Thursday, 22'nd Jan 2026
Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death risk by 49% in high-risk melanoma.
Moderna is curbing investment in vaccine trials due to US backlash
11:20am, Thursday, 22'nd Jan 2026
Moderna CEO Stephane Bancel said the company doesn't plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials https://bloom.bg/3LNHufg
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV
11:08am, Thursday, 22'nd Jan 2026
Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thurs
Moderna CEO Says Vaccine Scrutiny Is Curbing Trials
10:08am, Thursday, 22'nd Jan 2026
Moderna CEO Stephane Bancel says the company does not plan to invest in late-stage vaccine trials because of growing scrutiny of immunizations from US officials. He speaks with Lisa Abramowicz at the
Live Nasdaq Composite: Tech Shines as Relief Rally Proves It Has Legs
09:43am, Thursday, 22'nd Jan 2026
Live Updates Economy Expands 24 minutes ago Live The U.S. economy is humming along, thanks to a resilient consumer and robust capex spending in corporate America. The latest data have revealed that GD
What's Happening With Moderna Stock?
09:15am, Thursday, 22'nd Jan 2026
Moderna stock surged 16% yesterday after receiving promising clinical trial results for its experimental skin cancer vaccine. The firm is working on mRNA-1893/V940, a personalized cancer vaccine devel
Small-Cap Growth Without Dividends: What NUSC's 1.4 Beta Really Costs Investors
08:06am, Thursday, 22'nd Jan 2026
Small-cap stocks have historically rewarded patient investors willing to endure volatility in exchange for growth potential.
Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally.
06:27am, Thursday, 22'nd Jan 2026
Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.
Stock Market Today: S&P 500, Dow Jones Futures Rise As Trump Scales Down EU Tariff Threats—Microsoft, Moderna, Intel In Focus
05:19am, Thursday, 22'nd Jan 2026
U.S. stock futures rose on Thursday following Wednesday's gains. Futures of major benchmark indices were higher.
Why Moderna Stock Surged Today
06:51pm, Wednesday, 21'st Jan 2026
Moderna's and Merck's partnership could help to advance cancer care. A promising skin cancer trial might have broader implications for other types of tumor treatments.
Live Nasdaq Composite: Markets Dodge Geopolitical Bullet as Optimism Returns
10:05am, Wednesday, 21'st Jan 2026
Live Updates Highs and Lows 19 minutes ago Live Netflix stock sunk to a new 52-week low today to below $82 per share. On the other side of the spectrum, AMD (Nasdaq: AMD) is soaring, up 8.5% on the da
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
07:17pm, Tuesday, 20'th Jan 2026
Moderna (MRNA) closed at $43 in the latest trading session, marking a +2.8% move from the prior day.
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
03:31pm, Tuesday, 20'th Jan 2026
In a blast from the past, COVID-19 vaccine developer Moderna NASDAQ: MRNA just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three yea
Moderna, Merck Report Positive Results From Cancer-Vaccine Study
06:58am, Tuesday, 20'th Jan 2026
Moderna and Merck's cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.
